<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896361</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10125</org_study_id>
    <nct_id>NCT02896361</nct_id>
  </id_info>
  <brief_title>Burst Optimized Stimulation Study</brief_title>
  <acronym>BOSS</acronym>
  <official_title>Burst Optimized Stimulation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medizinische Einrichtungen der Universität Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Duisburg GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NKO Sint-Augustinus Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to evaluate the therapeutic efficacy of burst microdosing
      stimulation paradigms in patients with chronic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized, double-blinded crossover study designed to
      compare conventional burst stimulation parameters to two different burst microdosing
      paradigms.

      Subjects will be randomized 1:1:1 to one of the three groups. Each group will evaluate all 3
      stimulation paradigms in different order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) for Pain</measure>
    <time_frame>assessed every 2 weeks after each intervention, for a total of 6 weeks</time_frame>
    <description>Standard evaluation of pain intensity. Scale goes from 0 to 100 millimiters. 0 means no pain, 100 means strongest imaginable pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>assessed every 2 weeks after each intervention, for a total of 6 weeks</time_frame>
    <description>European Quality of life questionnaire 5 dimensions. Range goes from 0 to 1. 0 represents low quality of life, 1 represents high quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Preference</measure>
    <time_frame>assessed 6 weeks after baseline at the last follow up visit</time_frame>
    <description>questionnaire to identify preferred stimulation paradigm. multiple choice questionnaire. Possible answers were
first intervention
second intervention
third intervention
no preference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>assessed every 2 weeks after each intervention, for a total of 6 weeks</time_frame>
    <description>questionnaire on satisfaction with current therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>assessed over 6 weeks of study participation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Stimulation order 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimulations delivered in following order:
Standard burst
Burst Microdosing 1
Burst Microdosing 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stimulation order 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimulations delivered in following order:
Burst Microdosing 1
Burst Microdosing 2
Standard burst</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stimulation order 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimulations delivered in following order:
Burst Microdosing 2
Standard burst
Burst Microdosing 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol</intervention_name>
    <description>Stimulation parameters are reprogrammed from original values to study defined ones</description>
    <arm_group_label>Stimulation order 1</arm_group_label>
    <arm_group_label>Stimulation order 2</arm_group_label>
    <arm_group_label>Stimulation order 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has been implanted with a commercially available SJM spinal cord stimulator
             for controlling chronic intractable pain associated with back and/or leg pain;

          -  Subject has been exclusively using burst stimulation for at least three months;

          -  Subject is 18 years of age or older;

          -  Subject's pain-related medication regimen was stable in the 4 weeks prior to the
             screening evaluation;

          -  Subject agrees not to add or increase pain-related medication from enrollment through
             the study duration;

          -  Subject is willing to cooperate with the study requirements including compliance with
             the regimen and completion of all office visits;

        Exclusion Criteria:

          -  Subject is currently participating in a clinical investigation study that includes an
             active treatment arm;

          -  Subject is currently receiving, applying or considering seeking workers compensation,
             or is involved in disability litigation;

          -  Subject has a non SJM neuromodulation device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lalit Venkatesan, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Devices</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NKO Sint-Augustinus</name>
      <address>
        <city>Antwerpen</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Duisburg GmbH</name>
      <address>
        <city>Duisburg</city>
        <state>North Rhine-Westphalia</state>
        <zip>47055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universität Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <results_first_submitted>August 3, 2018</results_first_submitted>
  <results_first_submitted_qc>May 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2019</results_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02896361/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>29 patients were screened for elegibility between july 2016 and may 2017 Dusseldorf (GER) and Wilrijk (BEL)</recruitment_details>
      <pre_assignment_details>27 of the 29 participants received the study intervention. Of those did not receive study intervention, 1 did not meet inclusion/exlusion criteria and 1 was withdrawn for non compliance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stimulation Order 1</title>
          <description>Stimulations delivered in following order:
Standard burst for 2 weeks
Burst Microdosing 1 for 2 weeks
Burst Microdosing 2 for 2 weeks
Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol: Stimulation parameters are reprogrammed from original values to study defined ones</description>
        </group>
        <group group_id="P2">
          <title>Stimulation Order 2</title>
          <description>Stimulations delivered in following order:
Burst Microdosing 1 for 2 weeks
Burst Microdosing 2 for 2 weeks
Standard burst for 2 weeks
Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol: Stimulation parameters are reprogrammed from original values to study defined ones</description>
        </group>
        <group group_id="P3">
          <title>Stimulation Order 3</title>
          <description>Stimulations delivered in following order:
Burst Microdosing 2 for 2 weeks
Standard burst for 2 weeks
Burst Microdosing 1 for 2 weeks
Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol: Stimulation parameters are reprogrammed from original values to study defined ones</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>emergenge of several new painful regions</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline information collected from the two patients that exited the study before receiving intervention was included in the basline analysis</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Baseline characteristics for all subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale (VAS) for Pain</title>
        <description>Standard evaluation of pain intensity. Scale goes from 0 to 100 millimiters. 0 means no pain, 100 means strongest imaginable pain</description>
        <time_frame>assessed every 2 weeks after each intervention, for a total of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microdosing A(5:5)</title>
            <description>Microdosing A: five seconds of Burst SCS alternating with five seconds of no stimulation</description>
          </group>
          <group group_id="O2">
            <title>Microdosing B: 5:10</title>
            <description>Microdosing B: five seconds of Burst SCS alternating with ten seconds of no stimulation</description>
          </group>
          <group group_id="O3">
            <title>Continuous</title>
            <description>Continuously delivered burst SCS</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) for Pain</title>
          <description>Standard evaluation of pain intensity. Scale goes from 0 to 100 millimiters. 0 means no pain, 100 means strongest imaginable pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.88" spread="23.5"/>
                    <measurement group_id="O2" value="48.60" spread="21.48"/>
                    <measurement group_id="O3" value="46.76" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D</title>
        <description>European Quality of life questionnaire 5 dimensions. Range goes from 0 to 1. 0 represents low quality of life, 1 represents high quality of life</description>
        <time_frame>assessed every 2 weeks after each intervention, for a total of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microdosing A(5:5)</title>
            <description>Microdosing A: five seconds of Burst SCS alternating with five seconds of no stimulation</description>
          </group>
          <group group_id="O2">
            <title>Microdosing B: 5:10</title>
            <description>Microdosing B: five seconds of Burst SCS alternating with ten seconds of no stimulation</description>
          </group>
          <group group_id="O3">
            <title>Continuous</title>
            <description>Continuously delivered burst SCS</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D</title>
          <description>European Quality of life questionnaire 5 dimensions. Range goes from 0 to 1. 0 represents low quality of life, 1 represents high quality of life</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.2"/>
                    <measurement group_id="O2" value="0.62" spread="0.19"/>
                    <measurement group_id="O3" value="0.59" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Preference</title>
        <description>questionnaire to identify preferred stimulation paradigm. multiple choice questionnaire. Possible answers were
first intervention
second intervention
third intervention
no preference</description>
        <time_frame>assessed 6 weeks after baseline at the last follow up visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stimulation Order 1</title>
            <description>Stimulations delivered in following order:
Standard burst for 2 weeks
Burst Microdosing 1 for 2 weeks
Burst Microdosing 2 for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Stimulation Order 2</title>
            <description>Stimulations delivered in following order:
Burst Microdosing 1 for 2 weeks
Burst Microdosing 2 for 2 weeks
Standard burst for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Stimulation Order 3</title>
            <description>timulations delivered in following order:
Burst Microdosing 2 for 2 weeks
Standard burst for 2 weeks
Burst Microdosing 1 for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Preference</title>
          <description>questionnaire to identify preferred stimulation paradigm. multiple choice questionnaire. Possible answers were
first intervention
second intervention
third intervention
no preference</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>first intervention</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>second intervention</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>third intervention</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no preference</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction</title>
        <description>questionnaire on satisfaction with current therapy</description>
        <time_frame>assessed every 2 weeks after each intervention, for a total of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microdosing A(5:5)</title>
            <description>Microdosing A: five seconds of Burst SCS alternating with five seconds of no stimulation</description>
          </group>
          <group group_id="O2">
            <title>Microdosing B: 5:10</title>
            <description>Microdosing B: five seconds of Burst SCS alternating with ten seconds of no stimulation</description>
          </group>
          <group group_id="O3">
            <title>Continuous</title>
            <description>Continuously delivered burst SCS</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction</title>
          <description>questionnaire on satisfaction with current therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neither satisfied or dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <time_frame>assessed over 6 weeks of study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Baseline characteristics for all subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <units>percentage of patients with AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Burst</title>
          <description>reporting &quot;per intervention&quot; adverse events experienced while standard continuous burst was delivered</description>
        </group>
        <group group_id="E2">
          <title>Burst Microdosing 1</title>
          <description>reporting &quot;per intervention&quot; adverse events experienced while burst microdosing 1 was delivered</description>
        </group>
        <group group_id="E3">
          <title>Burst Microdosing 2</title>
          <description>reporting &quot;per intervention&quot; adverse events experienced while burst microdosing 2 was delivered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral ISG syndrome</sub_title>
                <description>One subject reported an adverse event 35 days after randomization to Group 2. The subject developed a new pain condition, bilateral ISG syndrome after enrollment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Filippo Agnesi, PhD</name_or_title>
      <organization>Abbott Neuromodulation</organization>
      <phone>972-526-4860</phone>
      <email>filippo.agnesi@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

